Vitruvius Therapeutics gets FDA nod for vitamin B-12 injectionVitruvius Therapeutics has received the FDA's blessing for its vitamin B-12 injection, which had a market value of roughly $74.3 million for the year ended September 2018. Teva gets FDA green light for first generic SabrilTeva has received the Food and Drug Administration's approval for the first generic of Lundbeck's Sabril. Amneal gets FDA nod for generic Exelon patch The FDA has approved Amneal's generic Exelon patch, which had a market value of roughly $225 million. Teva, Amgen resolve generic Sensipar dispute Teva has agreed to stop selling its generic Sensipar after settling recent litigation with Amgen. AAM joins newly formed Coalition Against Patent Abuse The Association for Accessible Medicines has joined the Coalition Against Patent Abuse, a new stakeholder association that is focused on fighting abuses of the patent system. Ferring Pharmaceuticals acquires generic ganirelix acetate injection rights Ferring has acquired U.S. commercialization rights for generic ganirelix acetate injection from Sun Pharma. Camber launches generic Albenza Camber is debuting a generic Albenza for the treatment of tapeworms and other parasites. FDA approves Lupin's generic Latuda Lupin has received the FDA's approval for generic Latuda tablets, which had a market value of roughly $3.2 billion. Alembic gets approval for 2 generics The FDA has approved Alembic's generic Mirapex and Patanol, which had a market value of roughly $38.6 million, and $61 million, respectively. Lupin's generic Onfi gets FDA approval Lupin has received the Food and Drug Administration's green light for generic Onfi, which had a market value of roughly $260.2 million. First Previous 185 186 187 188 189 Next Last